Amylx Pharmaceuticals Inc vs YieldMax NVDA Option Income Strategy ETF — how do they compare? Amylx Pharmaceuticals Inc trades at $23.96 (market cap $2.64B), while YieldMax NVDA Option Income Strategy ETF trades at $12.87. The key difference: Amylx Pharmaceuticals Inc is trading nearer its 52-week high, YieldMax NVDA Option Income Strategy ETF nearer its low. Which is the better fit depends on your goals.
| AMLX | NVDY | |
|---|---|---|
Market Cap | $2.64B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $24.19 | $17.96 |
52-Week Low | $7.82 | $11.58 |
Enterprise Value | $2.39B | — |
Trailing returns across standard periods
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →NVDY is an actively managed ETF that pursues a synthetic covered call strategy on NVIDIA Corporation (NVDA) stock. The fund primarily sells call options on NVDA and invests in U.S. Treasury securities and other high-quality collateral. Its goal is to generate monthly income from the option premiums. This strategy provides exposure to the high-growth potential of NVDA while seeking to deliver a high yield, though it caps the potential capital appreciation of the stock.
Read more on NVDY →